હોમ › મલ્ટિપલ માયલોમા › નોર્થ કેરોલિના › Durham
Durham, NC માં મલ્ટિપલ માયલોમા ક્લિનિકલ ટ્રાયલ્સ
Durham (લગભગ 30 માઇલની અંદર) ની સાઇટ્સ પર મલ્ટિપલ માયલોમા માટે 37 અભ્યાસો ભાગીદારો શોધી રહ્યા છે. કોઈ અભ્યાસ ખોલો અને જુઓ કે કોઈ જોડાઈ શકે છે અને અભ્યાસ ટીમ સાથે સંપર્ક કેવી રીતે કરવો.
અધિકૃત અભ્યાસ ટેક્સ્ટ (અંગ્રેજી)
અહીં અભ્યાસ માટે ભરતી કરી રહ્યા છો? આ પેજની ટોચ પર તેને ફીચર કરો — 30 દિવસ માટે $99 →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
ભરતી ચાલુ છેફેઝ 3
- Research Site, Chapel Hill · 10 માઇલ દૂર
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 3
- Duke University Medical Center, Durham
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
ભરતી ચાલુ છેફેઝ 2
- Duke University Medical Center, Durham
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 3
- Durham VAMC, Durham
- University of North Carolina, Chapel Hill · 10 માઇલ દૂર
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
ભરતી ચાલુ છેફેઝ 3
- Durham VAMC, Durham
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
ભરતી ચાલુ છેફેઝ 2/3
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill · 10 માઇલ દૂર
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
ભરતી ચાલુ છેફેઝ 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 માઇલ દૂર
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
ભરતી ચાલુ છેફેઝ 3
- Duke University, Durham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 2
- University of North Carolina Medical Center, Chapel Hill · 10 માઇલ દૂર
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
ભરતી ચાલુ છેફેઝ 1/2
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill · 10 માઇલ દૂર
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
ભરતી ચાલુ છેફેઝ 2
- Duke University Health System, Durham
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 1
- University of North Carolina Hospitals at Hillsborough, Hillsborough · 13 માઇલ દૂર
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
ભરતી ચાલુ છેફેઝ 1/2
- GSK Investigational Site, Chapel Hill · 10 માઇલ દૂર
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 1
- Duke University Hospital, Durham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
ભરતી ચાલુ છેફેઝ 1/2
- Research Site, Durham
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
ભરતી ચાલુ છેફેઝ 3
- Research Site, Durham
- Research Site, Chapel Hill · 10 માઇલ દૂર
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
ભરતી ચાલુ છે
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · 10 માઇલ દૂર
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
ભરતી ચાલુ છેફેઝ 1
- Duke Cancer Center, Durham
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 2
- UNC Hospitals Adult Oncology Clinics, Chapel Hill · 10 માઇલ દૂર
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
ભરતી ચાલુ છેફેઝ 1/2
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill · 10 માઇલ દૂર
Selinexor and Backbone Treatments of Multiple Myeloma Patients
ભરતી ચાલુ છેફેઝ 1/2
- Duke Institute of Cancer/ Duke University, Durham
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 1
- University of North Carolina /ID# 251203, Chapel Hill · 10 માઇલ દૂર
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
ભરતી ચાલુ છેફેઝ 1
- University of North Carolina at Chapel Hill, Chapel Hill · 10 માઇલ દૂર
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
ભરતી ચાલુ છેફેઝ 2
- University of North Carolina (Data Collection Only), Chapel Hill · 10 માઇલ દૂર
Registry of Older Patients With Cancer
ભરતી ચાલુ છેઅવલોકનકારી અભ્યાસ
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 માઇલ દૂર
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
ભરતી ચાલુ છેફેઝ 3
- Duke University, Durham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
ભરતી ચાલુ છેફેઝ 2
- University of North Carolina, Chapel Hill · 10 માઇલ દૂર
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
ભરતી ચાલુ છેફેઝ 2
- Duke Comprehensive Cancer Center, Durham
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · 10 માઇલ દૂર
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 1
- University of North Carolina Hospitals at Hillsborough, Chapel Hill · 10 માઇલ દૂર
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
ભરતી ચાલુ છેફેઝ 1/2
- Duke University Health System (DUHS), Durham
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 1
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230, Hillsborough · 13 માઇલ દૂર
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
ભરતી ચાલુ છેફેઝ 1
- University of North Carolina, Chapel Hill · 10 માઇલ દૂર
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
ભરતી ચાલુ છેફેઝ 1
- University of North Carolina, Chapel Hill · 10 માઇલ દૂર
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
ભરતી ચાલુ છેફેઝ 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · 10 માઇલ દૂર
Registry for Adults With Plasma Cell Disorders (PCD's)
ભરતી ચાલુ છેઅવલોકનકારી અભ્યાસ
- North Carolina Cancer Hospital, Chapel Hill · 10 માઇલ દૂર
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
ભરતી ચાલુ છેઅવલોકનકારી અભ્યાસ
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 માઇલ દૂર
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 1
- Duke University Health System (DUHS), Durham
અન્ય શહેરોમાં મલ્ટિપલ માયલોમા ટ્રાયલ્સ
- New York City, NY60 અભ્યાસો
- Boston, MA42 અભ્યાસો
- Atlanta, GA41 અભ્યાસો
- Houston, TX38 અભ્યાસો
- Nashville, TN32 અભ્યાસો
- Denver, CO27 અભ્યાસો
- Rochester, MN24 અભ્યાસો
- St. Louis, MO24 અભ્યાસો
- Columbus, OH24 અભ્યાસો
- Baldwin Park, CA23 અભ્યાસો
- Chicago, IL22 અભ્યાસો
- Seattle, WA22 અભ્યાસો
Durham માં અન્ય અભ્યાસો
- સ્તન કેન્સર63 અભ્યાસો
- કેન્સર (બધા પ્રકાર)58 અભ્યાસો
- નોન-સ્મોલ સેલ લંગ કેન્સર39 અભ્યાસો
- મેટાસ્ટેટિક કેન્સર33 અભ્યાસો
- એક્યુટ માયલોઇડ લ્યુકેમિયા33 અભ્યાસો
- ફેફસાનું કેન્સર32 અભ્યાસો
- પ્રોસ્ટેટ કેન્સર32 અભ્યાસો
- કોલોરેક્ટલ કેન્સર28 અભ્યાસો
- ક્રોનિક લિમ્ફોસાઈટિક લ્યુકેમિયા27 અભ્યાસો
- ઓવેરિયન કેન્સર27 અભ્યાસો
- હૃદય અપૂરતાપણું26 અભ્યાસો
- પેન્ક્રિએટિક કેન્સર24 અભ્યાસો
ClinicalTrials.gov પરથી, તારીખ 5 ઑક્ટો, 2026 ના ડેટા સાથે. દરેક અભ્યાસની પોતાની પાત્રતા શરતો હોય છે; અભ્યાસ ટીમ નક્કી કરે છે કે કોઈ જોડાઈ શકે છે કે નહીં.